BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumours, and GATC Health ...

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.

Experimenting with chainsaw chain steel to create Damascus. This video covers the process of forging a solid bar from chain pieces, highlighting the challenges of using non-homogeneous material with ...